What is your new year’s resolution? Finally getting round to War and Peace (there’s a perfectly decent BBC adaptation if ...
After nearly 80 years, a long-lost creature thought to have vanished from the Australian landscape has been spotted once ...
In the space of a chance conversation at Spot On Marine a few years ago, skipper Brendan Freeman found himself the owner of a ...
Ambulance Victoria has declared a “Red Escalation” across the state in response to catastrophic fire danger across the state ...
A major police hunt involving the tactical response group and police aircraft has expanded after a gunman fled the scene in a ...
Armed with an Eras dial that lets you command decade-specific effects, the Fujifilm Mini Evo Cinema has soundly earned our interest.
The 2 ASX growth shares have endured volatility. Both Lendlease and Temple & Webster are emerging with a clearer strategy and ...
Loqus23 Therapeutics Ltd. has nominated LQT-23, a first-in-class allosteric oral small-molecule inhibitor of MSH3/MutSβ, as a development candidate for Huntington’s disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback